Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study Jin Sun YoonDeok Won HwangYoung Yiul Lee PRECLINICAL STUDIES 18 November 2015 Pages: 1 - 14
7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice Eileen G. RussellJianfeng GuoThomas G. Cotter PRECLINICAL STUDIES 12 November 2015 Pages: 15 - 23
Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts Jeffrey D. SerrillXuemei WanJane E. Ishmael PRECLINICAL STUDIES 12 November 2015 Pages: 24 - 40
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site Diane-Charlotte ImbsMarie-Noelle PaludettoFabienne Thomas PRECLINICAL STUDIES 16 November 2015 Pages: 41 - 48
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models Darlene BarnardH. Bruce DiazMark Marshall PRECLINICAL STUDIES 27 November 2015 Pages: 49 - 60
Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates Nirali N. ShahDiane E. ColeBrigitte C. Widemann PRECLINICAL STUDIES 10 December 2015 Pages: 61 - 65
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors Hiroshi NokiharaYasuhide YamadaTomohide Tamura PHASE I STUDIES 02 December 2015 Pages: 66 - 74
Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors Sanjay GoelSantiago ViteriRafael Rosell PHASE I STUDIES 02 December 2015 Pages: 75 - 83
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors Manik AminSusan E. MintonA. Craig Lockhart PHASE I STUDIES 01 December 2015 Pages: 84 - 95
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies Joleen M. HubbardGeorge KimAxel Grothey PHASE I STUDIES 18 November 2015 Pages: 96 - 103
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041) Joanne W. ChiuSebastien J. HottePhilippe L. Bedard PHASE I STUDIES Open access 19 December 2015 Pages: 104 - 111
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study Manish K. ThakurLance K. HeilbrunElisabeth I. Heath PHASE II STUDIES 18 November 2015 Pages: 112 - 118
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study Didier MeulendijksLaurens V. BeerepootAnnemieke Cats PHASE II STUDIES 08 December 2015 Pages: 119 - 128
Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin Lee-Chuan C. YehAsok BanerjeeJohn C. Lee SHORT REPORT 21 December 2015 Pages: 129 - 137